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Current anti-HIV drugs target several of viral enzymes that HIV requires to replicate 
and survive. Hyperactivation of the immune system is now recognized as the major 
driver of progression to AIDS and of the emergence of both AIDS-defining and non-
AIDS events which negatively impact upon morbidity and mortality despite fully 
suppressive ART. AV-HALTs are a new class of antiretrovirals that both reduce HIV 
replication and excessive immune activation. By targeting a human rather than a 
viral enzyme the chances of the virus developing resistance are decreased, an 
improvement over traditional antiretroviral drugs. The proof of concept for this new 
class of drugs was achieved with a Phase IIa study in which the HU/ddI combination 
(first generation AV-HALTs) safely achieved the goals established for the AV-HALT 
class. The idea of AV-HALTs was further expanded in order to join both the 
antiproliferative and antiviral activities into a single molecule. CDK9 inhibitors were 
tested with the goal to identify second generation AV-HALTs. Compounds with good 
toxicity and activity profile were moved to preclinical development and were tested 
for ADME properties and preliminary in vivo experiments in rodent species. In 
addition, CDK9 inhibitors were found to be active against other viruses such as HSV-
1, HSV-2, EBV and HPV. This class of compounds also proved to inhibit proliferation 
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Human Immunodeficiency Virus Type 1 (HIV-1) is a lentivirus of the family of the 
Retroviridae. The virus targets the host immune system (CD4+ T cells and 
monocytes) and HIV-1 infection is characterized by a decline in T cell count and 
function, leading to a weakened immune system. HIV-1 virion’s diploid genome 
consists of two single-stranded RNA molecules within a host-derived lipid bilayer. 
Infection of host cells by HIV-1 begins with the binding of the viral envelope 
glycoprotein (gp120) to specific receptors present at the plasma cell membrane. The 
main receptor for HIV-1 is the CD4 molecule which is expressed by T-helper 
lymphocytes, macrophages and dendritic cells. Binding of gp120 to CD4 molecule 
initiates the process of HIV-1 absorption to the target cell membrane followed by 
conformational changes in gp120 that enable it to bind to a co-receptor, the C-C 
chemokine receptor type 5 (CCR5) and the C-X-C chemokine receptor type 4 
(CXCR4). Further conformational changes occur prompting to the exposure of the 
viral envelope glycoprotein gp41 ultimately leading to viral envelope fusion with 
target cell membrane. 
Following entry of HIV-1 into the host cell, the viral core particle is released and the 
viral RNA is converted into double-stranded linear DNA by the viral reverse 
transcriptase. The core-DNA complex (or preintegration complex) is then imported 
into the nucleus of the host cell, nuclear entry is mediated by Vpr and Vif accessory 
proteins, as well as by nuclear localization signals. Viral integrase protein inserts the 
viral genome into the host cell chromosome in transcriptionallly active regions of the 
genome. Control of HIV-1 gene expression is regulated by both cellular and viral 
factors. The HIV-1 RNA genome contains 9 open reading frames and is about 9 
kilobases in length. After integration, cellular factors mediate transcription of viral 
transcription factors located on the pol or env genes. Tat protein increases the 
transcription rate. After env gene has been transcribed Rev protein binds both 
spliced RNA (used for structural proteins) and unspliced RNA (used for genome 
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packaging) mediating export from the nucleus. Viral structural proteins are located 
on the gag gene and are transcribed and translated into a pre-protein (pr55) which is 
cleaved upon maturation of the virus. Another pre-protein is derived from gag-pol 
and yields the viral protease, integrase and reverse transcriptase (RT). Env gene is 
transcribed and translated into a gp160 pre-protein which travels to the cell 
membrane where, during virion formation, it is cleaved into gp120 and gp41. Other 3 
regulatory proteins are obtained from env mRNA: Vpr (aids in the transport of cDNA 
into the nucleus), Vpu (aids in virion assembly) and Vif (important in maintaining 
infection efficiency). Figure 1 illustrates the HIV life cycle. 
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2.2. Transmission, natural course of HIV infection and epidemiology 
HIV can be transmitted mainly by three routes: unprotected sexual intercourse, blood 
transfusion and from mother to child during pregnancy. In the absence of treatment, 
HIV infection leads to a progressive loss of circulating CD4+ T lymphocytes which 
results in the immune dysfunction which is defined as AIDS (Acquired 
Immunodeficiency Syndrome).  
 















Since the beginning of the epidemic, almost 78 million people have been infected 
with the HIV virus and about 39 million people have died of HIV. Globally, 36.9 
million [34.3–41.4 million] people were living with HIV at the end of 2014. An 
estimated 0.8% of adults aged 15–49 years worldwide are living with HIV, although 
the burden of the epidemic continues to vary considerably between countries and 
regions. The highest prevalence of HIV infection remains in Sub-Saharan Africa, 
there were 25.8 million people living with HIV in 2014 and there were 790,000 AIDS-
related deaths (Table 1). 
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Standard antiretroviral therapy (ART) consists of the combination of at least three 
antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the 
progression of HIV disease. Significant reductions have been seen in rates of death 
and suffering when use is made of a potent ARV regimen, particularly in early stages 
of the disease. There are six major types of drugs used to treat HIV/AIDS: 
Entry Inhibitors interfere with the virus ability to bind to receptors on the outer surface 
of the cell it tries to enter. When receptor binding fails, HIV cannot infect the cell. 
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Fusion Inhibitors interfere with the virus ability to fuse with a cellular membrane, 
preventing HIV from entering a cell. 
CCR5 antagonists block the CCR5 coreceptor on the surface of the immune cells 
preventing HIV from entering the cell. 
RT Inhibitors prevent the HIV enzyme RT from converting single-stranded HIV RNA 
into double-stranded HIV DNA―a process called reverse transcription.  
Integrase Inhibitors block the HIV enzyme integrase, which the virus uses to 
integrate its genetic material into the DNA of the cell it has infected. 
Protease Inhibitors interfere with the HIV enzyme called protease, which normally 
cuts long chains of HIV proteins into smaller individual proteins. When protease does 
not work properly, new virus particles cannot be assembled. 
To prevent strains of HIV from becoming resistant to a type of antiretroviral drug, 
healthcare providers recommend that people infected with HIV take a combination of 
antiretroviral drugs. Nonetheless, inherent limitations in current ART (most notably 
difficult adherence, short- and long-term toxicities, treatment-emergent resistance, 
and cost) continue to be associated with these multi-drug regimens.  
In the course of chronic HIV infection a well-documented hyperactivation of the 
immune system occurs (Mahalingam 1993; Hunt 2003; Grossman 2006; Brenchley 
2006), leading to a continuous cycle of increased T cell hyperproliferation and, 
ultimately, systemic inflammation. Chronic immune stimulation is due to persistent 
HIV-1 replication, microbial translocation and other factors, resulting in the eventual 
exhaustion of the immune system, accelerated senescence and, consequently, the 
onset of AIDS despite maximally suppressive ART regimens (Finkel 1995; 
Grossman 2000; McCune 2001; Hellerstein 2003). 
Current anti-HIV therapy can significantly reduce viral replication and achieve 
‘‘undetectable’’ levels of circulating HIV RNA (i.e., less than 50 copies/mL), however 
immune system hyperactivation, cellular hyperproliferation and inflammation do not 
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return to normal levels (Hunt 2003; Lesho 2006; Evans 1998).  
This incomplete deactivation of the immune system is now considered the primary 
driver of a growing number of ‘‘non-AIDS defining events’’ including cardiovascular 
disease, liver disease, kidney disease, bone loss, increased rates of cancer, and 
accelerated aging even in individuals for whom today’s anti-HIV combinations have 
reduced the HIV virus to undetectable levels in their blood (Baker 2008; Ho 2010; 
Mitsuyasu 2008; Cauley 2007; Deeks 2003). 
There is a growing recognition that successful long-term therapy for the treatment of 
HIV-1 infection should be disease modifying, not only reducing replicating virus but 
also directly diminishing the excessive chronic activation of the immune system 
(Hunt 2003; Brenchley 2006; Douek 2003; Silvestri 2005).  
In order to address this unmet need, we developed an innovative core platform of 
antiviral-immune protective compounds called AntiViral-HyperActivation Limiting 
Therapeutics (AV-HALTs) designed to reduce both HIV-1 RNA levels and excessive 
chronic immune system hyperactivation. To accelerate drug development and 
establish the AV-HALT Proof of Concept in the treatment of HIV-1 in man, two 
available generic drugs, a direct-acting antiviral (didanosine, ddI) and a 
hyperactivation-limiting agent (hydroxyurea [HU]) were combined in a fixed-dose-
combination (FDC) capsule known as VS411. This formulation was studied in a 
multinational Phase IIa trial in which it exhibited excellent safety and tolerability as 
well as providing solid proof-of-concept evidence for the AV-HALT paradigm by 
reducing HIV-1 RNA levels, increasing CD4+ T cell counts and reducing the markers 
of immune system hyperactivation after only 28 days of therapy (Lori 2012). 
VS411 is not being developed further due to concerns over the long-term toxicities 
associated with didanosine but successfully established the proof of concept that 
AV-HALTs can combine antiviral efficacy with rapid reductions in the immune system 
activation associated with HIV-1 disease. Work has been underway to screen, 
identify and develop single-molecule, second-generation AV-HALTs.   
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2.4. Targeting CDK9 
Cyclin-dependent kinase 9 (CDK9) has been identified as a possible target for 
developing the new generation AV-HALTs. 
CDK9 is a serine/threonine kinase that forms the catalytic core of the positive 
transcription elongation factor b (P-TEFb) (Loyer 2005; Yu 2011; Malumbres 2005; 
Romano 2008). This enzyme stimulates transcription elongation of most protein 
coding genes by RNA polymerase II (RNAPII) (Nechaev 2011). Activity of CDK9 is 
dependent on binding to a regulatory cyclin subunit (cyclin T1, T2a or T2b, K) and is 
further regulated through association with other macromolecules.  
CDK9 has a typical protein kinase fold consisting of an N- and a C- terminal kinase 
lobe and a short C-terminal extension. The ATP-binding site is located between the 
N- and C-terminal lobes and contains highly conserved active site residues that 
coordinate ATP binding and phosphotransfer. Due to high sequence conservation 
among kinases and especially members of the CDK family, it is really challenging to 
generate selective CDK9 inhibitors (Krystof 2010; Wang 2008). 
The majority of CDK9 is complexed with cyclin T1 in nuclear speckles and a small 
fraction of CDK9 is found in an apparently uncomplexed form in the cytoplasm. 
Studies have shown that nuclear P-TEFb exists in two functionally distinct 
complexes. Half of nuclear P-TEFb is found as an inactive complex associated with 
HEXIM1 (Hexamethylene Bis-Acetamide Inducible 1) and 7SK snRNA (Li 2005). 
Transcriptionally active P-TEFb associates with the bromodomain-containing protein 
4 (Brd4) (Jang 2005). 
 
2.5. CDK9 and HIV 
During HIV-1 replication, the host RNAPII is recruited to the viral promoter within the 
long terminal repeat (LTR) and initiates transcription (Cujec 1997). RNAPII initiates 
transcription, but elongation of most of the transcripts is blocked by negative 
elongation factors (Fujinaga 2004; Ivanov 2000). The HIV-1 transcription 
transactivator Tat binds to the bulge of the HIV-1 RNA stem loop termed TAR 
(transactivation response element) that is found in all nascent HIV-1 messages and 
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recruits P-TEFb to the LTR (Price 2000; Zhou 2006). P-TEFb phosphorylates both 
the carboxyl-terminal domain (CTD) of RNAPII (Marshall 1996) and the negative 
elongation factors (Fujinaga 2004; Yamada 2006) allowing RNAPII to transition from 
abortive to productive elongation (Peterlin Mol Cell 2006). 
 
2.6. CDK9 and other viruses 
Significant amount of scientific evidence indicates that CDK9 is a key kinase 
involved in the life cycle not only of HIV but also of different viruses, including herpes 
viruses, flaviviruses and respiratory viruses. In the Herpes Simplex Virus type 1 
(HSV-1) life cycle, it has been reported that CDK9 interacts with the immediate-early 
viral protein ICP22 and promotes Polymerase II.  Inhibition of CDK9 through the 
CDK9 inhibitor DRB (5,6-dichlorobenzimidazone-1-β-D-ribofuranoside) or siRNA 
impedes viral transcription and causes a reduction in the expression of ICP22 
(infected cell protein 22)-regulated mRNA and the late herpes proteins (Durand 
2005; Ou 2013).  In addition, roscovitine, an inhibitor of both CDK2 and CDK9, has 
been shown to attenuate Herpes Simplex Virus type 2 (HSV-2) replication (Schang 
2002). Human Cytomegalovirus (HCMV) induces RNAPII CTD phosphorylation for 
immediate-early viral gene expression, coincident with increased CDK9 
activity/localization (Tamrakar 2005).  The HCMV encoded protein kinase, pUL69, 
has been shown to be strongly phosphorylated in HCMV-infected fibroblasts by 
CDKs.  Analysis of CDK inhibitors in a pUL69-dependent nuclear mRNA export 
assay provided evidence for the functional impairment of pUL69 under conditions of 
suppression of CDK activity.  Moreover, a direct impact of the complex CDK9/cyclin 
T1 has been demonstrated on the nuclear localization and activity of the viral 
regulator pUL69 (Rechter 2009, Feichtinger 2011). For Epstein-Barr Virus (EBV), it 
has been reported that the EBV encoded protein, EBNA 2 (Epstein-Barr nuclear 
antigen 2), phosphorylates RNAPII CTD in a CDK9 dependent manner, a dominant 
negative CDK9 can inhibit EBNA 2-activated transcription and the CDK9 inhibitor 
DRB can reduce the transcription rates of viral genes (Bark-Jones 2006).  Moreover, 
EBNA 2 activates the viral promoter Cp through the CDK9/cyclin T1 complex to 
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produce all EBNAs required for EBV induced immortalization (Palermo 2011).  
In a study it has been shown that recruitment of P-TEFb, which interacts with Brd4 in 
transcription activation, is important for transcription activation activity of E2. 
Furthermore, chromatin immunoprecipitation analyses demonstrate that P-TEFb is 
recruited to the actual papillomavirus episomes. Interaction of E2 with cellular 
chromatin through Brd4 correlates with its papillomavirus transcription activation 
function since JQ1(+), a bromodomain inhibitor that efficiently dissociates E2-Brd4 
complexes from chromatin, potently reduces papillomavirus transcription (Helfer 
2014). 
In Dengue Virus (DENV), the DENV core protein and P-TEFb work in concert to 
enhance the IL-8 gene expression associated with DENV infection (Li 2010).  In the 
Influenza virus life cycle, it has been reported that the CDK9/cyclin T1 complex 
serves as an adapter to mediate the interaction of vRNP (ribonucleoprotein) and 
RNAPII to promote viral transcription. Depletion of cyclin T1 by RNA interference has 
been shown to inhibit viral transcription and replication (Zhang 2010). In the case of 
Respiratory Syncytial Virus (RSV), CDK9 activity has been reported to be required 
for the RSV-inducible NF-kB-dependent gene expression (Brasier 2011). 
 
2.7. CDK9 and cancer 
To date, over 20 potent CDK inhibitors undergo phase I-II clinical trials in patients 
with different cancers (Lapenna 2009; Krystof 2010; Dickson 2009; Peyressatre 
2015). 
CDK9 inhibition leads to the downregulation of transcriptionally inducible genes with 
short half-lives, including cell cycle regulators and antiapoptotic factors (Lam 2001). 
Although the drugs target several CDKs, it has been proposed that the induction of 
apoptosis arises primarily due to the inhibition of CDK9 (Gojo 2002; MacCallum 
2005; Santo 2010; Lam 2001). Inhibition of transcription through inhibition of CDK9 
leads to a rapid decrease not only of D-type cyclins, that support uncontrolled 
proliferation, but also of antiapoptotic proteins XIAP (X-linked inhibitor of apoptosis 
protein) and Mcl-1 (Myeloid Cell Leukemia 1). Similarly, the induction of chronic 
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lymphocytic leukemia cells death induced by flavopiridol, SNS-032 or roscovitine is 
also mediated by the repression of transcription due to CDK9 inhibition and 
concomitant down-regulation of XIAP and Mcl-1 (Chen 2005; Chen 2009; Hahntow 
2004). A dependence on the expression of antiapoptotic proteins is not exclusive to 
multiple myeloma or chronic lymphocytic leukemia. Experimental compound CR8, a 
congener of roscovitine, potently induces apoptosis in neuroblastoma cells, 
accompanied by Mcl-1 down-regulation both at the mRNA and protein levels 
(Bettayeb 2010). Similarly, compound VER-54505 reduced levels of Mcl-1 and XIAP 
in human osteosarcoma cell line U2OS (Scrace 2008). As a part of the positive 
transcriptional regulatory complex, CDK9 interacts also with the androgen receptor 
(AR) to enhance transcription activity (Lee 2001). CDK9 regulates the androgen 
receptor through S81 phosphorylation and this is an important step in regulating not 
only its transcriptional activity, but also for prostate cancer cell growth (Gordon 
2010). It has been shown that pharmacological inhibition of CDK9 by flavopiridol 
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3. MATERIALS AND METHODS 
 
3.1. Compounds 
A library of novel synthetic CDK9 inhibitors has been screened in order to identify 
safe compounds with dual antiproliferative and antiviral activity (second generation 
AV-HALTs).  
 
3.2. In vitro CDK9/cyclin T assay 
The activity of the compounds described in the present invention can be determined 
by measuring the phosphorylation of a fluorescently-labeled peptide by human 
CDK9/cyclin T kinase complex by fluorescent polarization using a commercially 
available IMAP (Immobilized Metal Ion Affinity-Based Fluorescence Polarization) 
Screening Express Assay Kit (Molecular devices). 
Test compounds were diluted in 100% DMSO (dimethyl sulfoxide) to 5 mM stock 
concentration, then further dilutions were made in H2O or 100% DMSO to desirable 
concentrations. 
Each reaction consisted of 5 nM enzyme: CDK9/cyclin T (Proqinase cat# 0371-0345-
1), 400 nM TAMRA-Rbtide (synthetic 15-mer peptide derived from human 
retinoblastoma tumor suppressor protein labelled with TAMRA dye, Genecust 
Europe), 12 μM ATP (=Kmapp, Sigma-Aldrich) and kinase buffer: 20 mM MOPS pH 7 
(Sigma-Aldrich), 1 mM DTT (Sigma-Aldrich), 10 mM MgCI2 (Sigma-Aldrich), 0.01 % 
Tween 20 (Sigma-Aldrich). 
For each reaction, 4 or 6 μL containing TAMRA-Rbtide, ATP and kinase assay buffer 
were combined with 2 μL diluted compound in H2O or 0.028 μL compound in 100% 
DMSO. The kinase reaction was started by the addition of 2 μL diluted enzyme. The 
reaction was allowed to run for 1 hour at room temperature. The reaction was 
stopped by adding 15 µL IMAP beads (1:400 beads in progressive (100 % buffer A) 
1X buffer). After an additional 1 hour, fluorescent polarization (Ex: 550-10 nm, Em: 
590-10 nm, Dich: 561 nm) was measured using an Analyst GT (Molecular devices). 
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3.3. Drug toxicity analysis 
Peripheral blood mononuclear cells (PBMC) were obtained from healthy donors by 
separation over Ficoll-Hypaque (GE Healthcare). After separation PBMC were 
washed in RPMI 1640 medium (BioWest) supplemented with 10% heat-inactivated 
fetal bovine serum (FBS, Gibco BRL), 2 mmol/L L-glutamine, 50 IU/mL penicillin, and 
50 µg/mL streptomycin (all from BioWest), referred to as complete medium (CM), 
and the viable cells were counted by trypan blue (Gibco BRL) exclusion. PBMC were 
then suspended at 2 x 106 cell/mL in CM supplemented with 5 µg/mL of 
phytohemoagglutinin-P (PHA, Sigma Aldrich) in 75 cm2 flasks (Sarstedt) and 
cultured for 2 days at 37°C in a humidified atmosphere supplemented with 5% CO2. 
PBMC were then washed in CM, counted by trypan blue exclusion, suspended in 
CM supplemented with 20 IU/mL of interleukin-2 (IL-2, Boehringher-Mannerheim) 
and seeded in a 96-well plate (Costar Corning Incorporate) at 105 cells/well (200 µL 
CM per well). Cells were left untreated (NT) or treated with different concentrations 
of the compounds. After 7 days of incubation at 37°C cells were counted by trypan 
blue exclusion. Viability was expressed as the percentage of alive cells compared to 
the NT, indicated as 100%. Toxic dose 50% (TD50, concentration inducing 50% cell 
death compared to NT) was calculated by interpolation of the dose-response curve. 
 
3.4. Analysis of the effect of the compounds on cell proliferation and 
apoptosis 
CD4+ cells were separated by positive selection with anti-CD4 coated magnetic 
beads (Miltenyi Biotech Inc.) from peripheral blood mononuclear cells (PBMC) 
obtained from healthy, normal donors. Cells were stained with carboxyfluorescein 
succinimidyl ester (CFSE; Invitrogen) to trace cell divisions. Cells were suspended at 
a final concentration of 2.5 x 106 cells/mL in CM. CD4+ cells were cultured for 5 days 
without stimulation then re-suspended in CM supplemented with 5 μg/mL PHA, after 
2 additional days of culture, IL-2 at a concentration of 20 IU/mL was added, then 
cells were cultured for an additional 3 days. Cells were treated with compounds from 
day 1 to day 10. At day 10 proliferation was determined through CFSE flow 
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cytometric analysis. For data analysis, the mitotic index (M) was used, calculating 
the sum of mitotic events at each proliferation cycle. To extract a relative number, M 
was normalized to the total number of cells acquired using the equation M = ∑(Xn(T) 
– Xn(T)/2n), that gives the number of mitotic events from the experimentally obtained 
values of the proportion of T cells under each division peak n (Xn) and the total T 
cells (T). To study the effect of the compounds on apoptosis CD4+ cells were 
cultured as described above and at day 10 cells were stained with Annexin V and 7-
AAD (7-aminoactinomycin D), in order to determine the percentage of early, late and 
total apoptotic events. When possible IC50 (concentration increasing of 50% total 
apoptotic effect compared to control) was calculated.  
 
3.5. Study of the antiviral activity of the drugs on HIV-1 replication in 
resting/activated cells 
CD4+ cells were obtained as described above and then infected with HIV-1 NL 4.3 at 
a MOI (multiplicity of infection) of 0.001. Cells were cultured without stimulations for 
5 days then stimulated with PHA/IL-2 as described before. Cells were treated with 
compounds from day 1 to day 10. The control was left untreated. After 10 days of 
incubation at 37°C supernatants were harvested and HIV-1 p24 Ag was measured 
by ELISA (Enzyme-Linked ImmunoSorbent Assay, Helvetica Health Care) in order to 
determine viral replication.   
 
3.6. Mitochondrial toxicity 
BxPC-3 cells were rinsed with phosphate buffered saline (PBS), and incubated with 
0.55% trypsin and 0.2% EDTA (Biowest) for 5 min at 37°C. Fresh medium was then 
added and the viable cells were counted by trypan blue exclusion. BxPC-3 cells were 
plated in 6-well plates at a concentration of 2.5x105 cells/well. Every 7 days of 
culture the cells were split, counted and replated at the same starting concentration. 
At day 14 cells were harvested and stained with the lipophilic cationic probe JC-1 
(5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide, Molecular 
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Probes) and analyzed by flow cytometry to evaluate mitochondrial functionality. 
 
3.7. ADME (absorption, distribution, metabolism, and excretion) studies 
 
3.7.1. Thermodynamic solubility 
Thermodynamic solubility of compounds was determined in phosphate buffer pH 7.4, 
at room temperature by the shake flask method. Quantification of the samples was 
performed on calibration curves prepared by dilution in acetonitrile (ACN) of a 2 
mg/mL stock solution in DMSO.  
A calibration curve (10 points) has been prepared from the working standard 
solutions by the appropriate dilution with ACN. Saturated solutions of the compounds 
were prepared by incubating about 2 mg in 1 mL of buffer for 24h at room 
temperature (25°C) under agitation. At the end of the incubation samples were 
filtered, aliquots (3) were diluted in ACN 1:100  and each sample was then injected 
three times into LC-MS/MS (liquid chromatography and mass spectrometry). 
Samples of the calibration curve were analysed on Shimazu UFLC with API 4500 
Detector, Triple Quadrupole LC-MS/MS Mass spectrometer. 
 
3.7.2. In vitro absorption in Caco-2 
Caco-2 (colorectal adenocarcinoma, ATCC) monolayers were cultured on cell culture 
inserts. The transport from the apical to the basolateral side (A→B) across the Caco-
2 monolayer was determined by adding the test compound to the apical side. In the 
(B→A) experiment, the test compound is added in the basolateral side and collected 
in the apical side. 
After 2 hours of incubation, the basolateral side solution, together with the apical and 
the starting solutions, was analysed and quantified by LC-MS/MS. To maintain 
physiologically relevant conditions, the pH of the apical side was 6.5, while the pH of 
the basolateral side was 7.4. The apparent permeability (Papp) was calculated 
according to the following equation: 
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Papp = J/Co 
where: 
J=flux (dX/dt x A) and Co=donor concentration (μM) at t=0; dX/dt=change in mass 
(X, nmol) per time (t, sec), A=filter surface area (cm2). 
The apparent permeability of the test compounds, and their rank order, is always 
compared with two known reference compounds tested in the same experiment. 
Suggested absorption classification values are: 
Papp > 50 nm/s: high; 
Papp 10-50 nm/s: medium; 
Papp < 10 nm/s: low. 
 
3.7.3. Metabolic stability 
The metabolic stability of the test compound was assayed in microsomes (for phase 
I metabolism). The test compound was pre-incubated for 10 minutes at 37°C in the 
appropriate buffer at pH 7.4 with microsomes (human and rat). After the pre-
incubation period, the reaction was started (time 0) by adding the cofactors mixture; 
samples were taken at 30 minutes and added to acetonitrile containing an internal 
standard to stop the reaction. Samples were then centrifuged and supernatant 
analysed by LC-MS/MS. A control sample without cofactors was always added in 
order to check the chemical stability of test compound in the matrix. The rate 
constant k (min-1), derived for the exponential decay equation, is used to calculate 
the rate of intrinsic clearance (Cli) of the compound using the following equation: 
Cli (μL × min-1× mg protein-1) = k x V 
where: V (μL × mg protein-1) = incubation volume/mg protein added. 
 
3.7.4. Inhibition of cytochrome P450 
Inhibition of the most important cytochrome P450 isoforms (CYP1A2, CYP2C9, 
CYP2C19, CYP2D6, CYP3A4) was measured in specific assays, using specific 
substrates that become fluorescent upon CYP metabolism. Human recombinant 
P450 isoforms (Supersomes, Gentest) were employed together with the following 
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substrates: CEC (3-cyano-7-ethoxycoumarin) for CYP1A2 and CYP2C19; MFC (7-
methoxy-4-(trifluoromethyl)-coumarin) for CYP2C9; AMMC (3-[2-(N,N-diethyl-N-
methylammonium)ethyl]-7-methoxy-4-methylcoumarin) for CYP2D6; BFC (7-
benzyloxy-4-(trifluoromethyl)-coumarin) for CYP3A4. 
Control inhibitors were added in every experiment. Compound solutions were tested 
at single concentration (10 µM). The reaction was started by adding specific 
isoenzymes and substrates at 37°C. After the incubation period (15-45 minutes 
depending on the CYP isoform), the reaction was stopped and plates were read on a 
fluorimeter at the appropriate emission/excitation wavelengths. The percentage 
inhibition of control enzyme activity (without inhibitor) was calculated. 
 
3.8. Preliminary toxicology study 
The toxic profile of one compound was analyzed after single oral treatment at 500 
mg/kg (suspension formulation) and after 5-day repeated oral treatment at 100 
mg/kg (solution formulation) in CD1 mice. Satellite groups were also treated in 
parallel in order to evaluate the plasma exposure (pharmacokinetics, PK) after the 
administration of 500 mg/kg in suspension and prior and after the fifth day of 
treatment at 100 mg/kg. Formulations employed consisted of compound dissolved in 
5% DMSO (Sigma-Aldrich) and 95% of a solution of 20% Soluplus (Sigma-Aldrich)/  
80% buffer pH 2 (w/w). All animals were weighed before treatment on the day of 
treatment and every following day till day 7. Clinical signs and mortality were 
monitored and reported at regular intervals. 
Animals of PK group treated with 5x100 mg/kg were sampled from the mandibular 
plexus before the last treatment at day 5 (t=0)  and at  0.5, 1, 2, 4, 8, 24 and 48 hr 
after the last treatment. Animals of PK group treated with 500 mg/kg were sampled 
from the mandibular plexus at 0.5, 1, 2, 4, 8, 24 and 48 hr. 
Samples were analyzed on UFLC (Ultra Fast Liquid Chromatography) Shimazu 
AC20 coupled with a API 4500 Triple Quadrupole ABSciex. 
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3.9. PK study 
Oral bioavailability and pharmacokinetic parameters were determined in the male rat. 
DMSO was added to the pre-weighted compound and vortexed 1 min.  Solutol (after 
being heated at 50°C) was added to the compound and solution vortexed for 1 min.  
PBS was added slowly under agitation.  
 
Formulations used in the study are summarized below. 
Intravenous (IV) treatment: 3 mg/kg 
7.98 mg 5% DMSO (665 µL), 5% Solutol 
(665 µL) in PBS pH 7.4 (11.97 mL) 
Administration volume: 5 mL/kg 
Oral (per os, PO) treatment: 10 mg/kg 
22 mg 5% DMSO (550 µL), 5% Solutol 
(550 µL) in PBS pH 7.4 (9.9 mL). 
Administration volume: 5 mL/kg 
 
After IV treatment, blood was sampled from caudal vein at the following timepoints: 
3, 10, 30, 60, 120, 240, 480, 1440 minutes. 
After PO treatment (Oral gavage), blood was sampled from caudal vein at the 
following timepoints: 10, 30, 60, 120, 240, 360, 480 1440 minutes. Samples were 
analyzed on UFLC Shimazu AC20 coupled with a API 4500 Triple Quadrupole 
ABSciex.  
3.10. HSV assay 
Human foreskin fibroblast (HFF) cells were cultured in minimum essential media 
(MEM) with Earle’s salts supplemented with 10% fetal bovine serum (FBS) and 
standard concentrations of penicillin and gentamicin (Prichard 2008).  
A primary cytopathic effect (CPE) reduction assay was performed. Low passage (3-
10) HFF cells were trypsinized, counted, and seeded into 96 well tissue culture 
plates in 0.1 mL of MEM supplemented with 10% FBS. The cells were then 
incubated for 24 h at 37oC. The media was then removed and 100 µL of MEM 
Davide De Forni 
Antiviral-Hyperactivation limiting therapeutics for the treatment of viral diseases and cancer  
International PhD School in Biomolecular and Biotechnological Sciences - University of Sassari 
22 
containing 2% FBS was added to all but the first row. In the first row, 125 µL of 
media containing the experimental drug was added in triplicate wells. Media alone 
was added to both cell and virus control wells. The drug in the first row of wells was 
then diluted serially 1:5 throughout the remaining. The plates were then incubated for 
60 min and 100 µL of a virus suspension was added to each well, excluding cell 
control wells which received 100 µL of MEM. The plates were then incubated at 37oC 
in a CO2 incubator for three days. After the incubation period, media was aspirated 
and the cells stained with crystal violet in formalin for 4h. The stain was then 
removed and the plates were rinsed until all excess stain was removed. The plates 
were allowed to dry for 24 h and the amount of CPE in each row determined using a 
multiplate autoreader. EC50 (effective concentration 50%) and CC50 (cytotoxic 
concentration 50%) values were determined by comparing drug treated and 
untreated cells using a computer program. 
 
3.11. EBV assay 
A primary DNA hybridization assay was performed (Prichard 2007).  Assays for EBV 
were performed in Akata cells that were induced to undergo a lytic infection. Cells 
were maintained in RPMI 1640 supplemented with 10% FBS, L-glutamine, penicillin 
and gentamicin at 37°C in a humidified 5% CO2 atmosphere. Cells were passaged 2-
3 days prior to performing the assay. Experimental compounds were diluted in 96-
well plates to yield concentrations ranging from 20 to 0.0064 µM. Latently infected 
Akata cells were added to the plates to a final concentration of 4x105 cells/mL, 
induced to undergo a lytic infection and incubated for 72 h.   
An alkaline denaturation buffer (1.2 M NaOH, 4.5 M NaCl) was added to each well to 
denature the DNA and a 50 µL aliquot was aspirated through a nylon membrane. 
The membranes were then allowed to dry before equilibration in DIG Easy Hyb 
(Roche Diagnostics, Indianapolis, IN) at 56°C for 30 min. Specific digoxigenin (DIG)-
labeled probes were prepared for each virus and corresponded to coordinates 
96802–97234 in EBV genome. Membranes with EBV DNA were hybridized overnight 
and followed by sequential washes 0.2X SSC (Sodium Chloride Sodium Citrate) with 
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0.1% SDS (Sodium Dodecyl Sulphate) and 0.1X SSC with 0.1% SDS at the same 
temperature. Detection of specifically bound DIG probe was performed with anti-DIG 
antibody using the manufacturer’s protocol (Roche Diagnostics). An image of the 
photographic film was captured and quantified with QuantityOne software (Bio-Rad) 
and compound concentrations sufficient to reduce the accumulation of viral DNA by 
50% (EC50), were interpolated from the experimental data. Cell viability was 
assessed with the CellTiter-Glo Luminescent Cell Viability Assay (Promega). Briefly, 
assay plates were incubated at ambient temperature for 30 min then 50 µL of 
CellTiter-Glo reagent was added to each well and the plates were mixed for 2 min on 
an orbital shaker to lyse the cells. Plates were then incubated for an additional 10 
min at ambient temperature and the luminescence was quantified on a luminometer. 
CC50 (cytotoxic concentration 50%) was calculated. 
 
3.12. HPV assay 
A transient replication of HPV origin-containing plasmid in transfected HEK293 
(human embryonic kidney) cells was performed. In this assay, vectors for expression 
of an HPV genotype-matched set of viral E1 and E2 proteins along with an HPV ori-
containing plasmid were cotransfected into HEK293 cells. Cells were cultured in the 
absence or presence of the test compounds at 1, 10, and 100 µM. Low molecular 
weight DNA was harvested 2 days post-transfection and digested with Dpn1 and 
exonuclease III to remove unreplicated transfected plasmid DNA. The replicated 
DNA was then subjected to real time qPCR (quantitative polymerase chain reaction) 
analyses in triplicate. Two controls were performed. One was to omit the E1 
expression vector to provide a background amount of undigested and unreplicated 
DNA. The other, positive control was treatment with the known inhibitor cidofovir. A 
toxicity assay based upon cell viability at the time of harvest on day 2 was performed 
alongside each transient replication assay in HEK293 cells. Compounds were added 
4 hours post transfection  at 1, 10, or 100 µM  for a total exposure of  44 hr.  Cell 
viability was evaluated through trypan blue staining. EC50 (effective concentration 
50%) and CC50 (cytotoxic concentration 50%) values were determined. 
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3.13. MTS assay in cancer cell lines 
The antiproliferative effect of the compounds was investigated in vitro in the following 
cell lines: 
Jurkat: T cell leukemia cell line 
HEC1A: endometrial carcinoma cell line 
A2780: ovarian carcinoma cell line  
MNK-45: gastric carcinoma cell line 
H1229: lung cancer cell line 
The cell lines were routinely maintained in RPMI supplemented with 1% glutamine 
(Biowest) and 10% fetal bovine serum (Gibco). The cytotoxic activity of the selected 
compounds was tested in the 5 cell lines using standardized MTS [(3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)] 
cytotoxic assays. Briefly, exponentially growing cells were seeded into 96-well plates 
at their optimal density in complete medium. 48-72 hours later cells were treated or 
not with seven different final concentrations (10, 5, 1, 0.5, 0.1, 0.05, 0.01 µM) of the 
selected compounds for 72 hours using six replicates each concentration. Drug 
dilutions were be performed in medium. Drug treatment lasted 72 hours at the end of 
which cell viability was assessed by MTS Colorimetric Assay (Promega). The 
experiment was repeated twice for each cell line. The Inhibitory Concentration 50% 
(IC50) values were obtained by interpolating the generated dose-response.  
 
3.14. Mouse Xenograft Model 
Experiment was performed in collaboration with Mario Negri Institute of 
Pharmacological Research (Milan). The test compound was dissolved in N-methyl 
pyrrolidone (NMP) 5% (v/v), Polyethylene glycol 400 (PEG400) 85% (v/v) and Water 
10% (v/v) to give a final 5 mg/mL solution. H1299 cell line was maintained in RPMI 
1640 medium (Biowest), supplemented with 10% Foetal Bovine Serum (Gibco) and 
1% glutamine (Biowest). 
The experiment was performed using six-week old athymic female mice, provided by 
Harlan Italy Srl. Mice  were maintained in the animal house under controlled 
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conditions (constant and controlled temperature and humidity) that allows to keep 
the Specific Pathogen Free status. Feeding regimen  was ad libitum. To obtain tumor 
xenografts, 200 µL of cell suspension containing 7x106 H1299 cells were sub-
cutaneously injected into the flanks of each mouse. The growing tumor masses were 
measured through a Vernier caliper, and the tumor weights (1 mm3 = 1 mg) were 
calculated by the formula: length x (width)2/2. When tumor load reached about 120 
mg, mice were randomized into the experimental groups, with body weight and 
tumor mass distributions balanced between the two groups. Mice were randomized 
in the following study groups: 
• Vehicle (9 animals) 
• Test compound 50 mg/kg/day (10 animals) 
Compound and vehicle were orally administered at a dose volume of 10 mL/kg daily 
for 15 consecutive days (until day 35 post tumor implant).  
Tumor size and mouse body weight were recorded three times a week from 
treatment start until the end of the study. Drug efficacy was calculated as T/C%, 
where T and C are the mean tumor weights of treated and control groups, 













Davide De Forni 
Antiviral-Hyperactivation limiting therapeutics for the treatment of viral diseases and cancer  




4.1. Screening of CDK9 inhibitors 
A library of potential CDK9 inhibitors was screened in biochemical assay for CDK9 
activity and selected hits (IC50 values < 1 µM) were tested in biological assay to 
determine AV-HALT characteristics.  
Chemical structure of these compounds can not yet be revealed because 
compounds deriving from this library are still under active development by the 
company ViroStatics and covered by confidentiality measures. 
 A panel of tests has been optimized in order to characterise compounds including 
measures of toxicity (viability, apoptotic effect, mitochondrial toxicity) and measures 
of activity (inhibition of cell proliferation, inhibition of HIV replication). The goal was to 
find compounds with a good toxicity profile and inhibiting both proliferation of the 
cells and viral replication within a single chemical entity (i.e. AV-HALT compounds).  
VS411 is the comparator prototype AV-HALT and was employed in all experiments 
as a reference being already tested in clinical studies. A concentration of 100 µM 
hydroxyurea and 2 µM didanosine (corresponding to the in vivo peak plasma 
concentrations after administration of 600 mg hydroxyurea and 400 mg didanosine, a 
dose combination that proved to be both active and safe in clinical trial) was chosen 
to be tested in vitro as a reference to determine ranges of toxicity and activity for the 
screening of the compounds. 
 
4.2. Determination of cytotoxicity in peripheral blood mononuclear cells  
PHA/IL-2 stimulated peripheral blood mononuclear cells were exposed to different 
concentrations of the compounds for 7 days. Then viability was determined through 
Trypan blue staining and expressed as percentage of untreated control 
(control=100% viability). A dose response curve was built for each of the compounds 
in order to determine the TD50 by interpolation of the data. An example of a dosage-
response relationship is shown in Figure 3 for one representative compound. 
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Viability of VS411 (100 µM HU/2 µM ddI) is indicated by the red line (80% viability 
compared to untreated control) while dotted line shows how TD50 is interpolated. 
 
4.3. Determination of apoptotic effect in CD4+ T cells 
CD4+ T cells derived from peripheral blood mononuclear cells by magnetic bead 
positive separation were exposed to different concentrations of the drugs for 10 
days. Apoptotic events were then detected through Annexin V/7-AAD staining and 
cytofluorimetric analysis allowing determination of both early (Annexin V+/7-AAD-) 
and late (Annexin V+/7-AAD+) apoptotic events. Percentage of apopotic cells was 
compared to control and VS411 in order to identify and exclude those compounds 
being more proapototic than VS411 and in general inducing more than 30% total 
apoptotic events compared to untreated control. 
A picture of the apoptotic events induced by compound VS1 is shown in Figure 4 in 
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Both compound VS1 and VS411 did not induce significant apoptotic effect compared 
to untreated control. There were no relevant differences between early and late 
apoptotic events at the tested doses. 
 
4.4. Determination of mitochondrial toxicity 
The human pancreatic cell line BxPC3 was exposed to different concentrations of 
the compounds, after 14 days on treatment cells were stained with JC-1 and 
analyzed by flow cytometry. MTI was calculated and compared to that of VS411 in 
order to exclude compounds inducing a damage to mitochondrial membrane.  
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VS411 induces mitochondrial toxicity (MTI=61), in fact didanosine (the antiviral 
component of this drug combination) is known to cause this effect in vitro and 
increases risk of pancreatitis and hepatitis in vivo (Benbrik J Neurol Sci 1997; 
Bissuel J Intern Med 1994; Brinkman AIDS 1998). VS1 did not induce mitochondrial 
toxicity at the tested concentrations (at concentrations inhibiting both cellular 
proliferation and HIV replication). 
 
4.5. Determination of antiproliferative effect in CD4+ T cells 
In a 10 days experiment cells were stained with the tracer CFSE on Day 1 of the 
experiment and analyzed by flow cytometry in order to determine the number of 
mitotic events and the mitotic index. Antiproliferative activity (AP) was calculated as 
the inhibition of cell proliferation = 100 minus the % mitotic index compared to the 
control (AP of control = 0%). AP50 was calculated by interpolation of the dose 
response curve as shown in Figure 6. Target was not to completely suppress cell 
proliferation in order to avoid immune suppression in vivo. 
VS411 antiproliferative activity is shown by the orange line (80% inhibition of cell 














VAL VS411 VS1 0.5 µM VS1 0.17 µM VS1 0.05 µM
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VS411 (100 µM HU/2 µM ddI) inhibited cell proliferation of 90%. VS1 had a strong 
antiproliferative effect with an AP50 value of 0.1 µM. 
 
4.6. Determination of antiviral effect  
Effect on HIV replication was assessed in resting/stimulated CD4+ cells infected with 
a laboratory strain of HIV-1 and exposed to different concentrations of compounds 
for 10 days. Viral replication was measured at the end of the experiment through 
determination of levels of protein p24 by ELISA. Antiviral activity (AV) was calculated 
as 100 minus the % p24 compared to the control (AV of control = 0%). AV50 was 
calculated by interpolation of the dose-response curve with the final goal to identify 
those compounds more active in inhibiting HIV replication. An example of antiviral 
activity dose-response curve is shown in Figure 7 below. 
VS411 anti-HIV activity is shown by the orange line (90% inhibition of virus 
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VS411 (100 µM HU/2 µM ddI) showed a 90% inhibition of viral replication. VS1 
strongly inhibited HIV replication with an AV50 of 0.03 µM.  
 
4.7. Identification of hit compounds 
All the parameters calculated along the screening of the library of CDK9 inhibitors 
were employed to identify those compounds to be moved ahead in the preclinical 
development.  
Below is a table listing three promising candidates (hits) identified during the initial 
screening. 
 











Compound TD50 (µM) AP50 (µM) AV50 (µM) MTI50 (µM) IC50 (µM) 
VS12 4 0.05 0.05 >1.5 >10 
VS18 20 0.07 0.15 >1.5 15 


















0,01 0,1 1 10
VS411 
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Therapeutic indexes (or windows) were calculated and used to select the most active 
and safe compounds.  
TI (AP) = TD50/AP50 
TI (AV) = TD50/AV50 
 
Table 3. Therapeutic indexes 
Compound 
ID 
TI (AP) TI (AV) 
VS12 80 80 
VS18 286 133 
VS23 106 142 
 
 
4.8. Clinical candidate selection 
The compounds were tested for preliminary ADME characteristics such as solubility, 
metabolic stability, CYP450 inhibition and permeability in Caco-2 cells. 
This class of compounds showed poor solubility in aqueous ambient (about 1 µM in 
phosphate buffer pH 7.4 as per thermodynamic solubility determination). 
Metabolic stability of the test compounds was assayed in microsomes from different 
species.  
  







VS12 84.5 ± 3.25 64.4 ± 0.85 
VS18 586.4 ± 11.9 115.2 ± 0.1 
VS23 745.7 ± 2.4 89.6 ± 4.0 
 
The three compounds showed high levels of clearance i.e. drug metabolism through 
liver microsomes was quite elevated, thus indicating a low metabolic stability of the 
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Inhibition of the most important CYP450 isoforms (CYP1A2, CYP2C9, CYP2C19, 
CYP2D6, CYP3A4) was measured in specific assays, using specific substrates that 
become fluorescent upon CYP metabolism. 
 
Table 5. CYP450 inhibition 
 CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A4 
Compound 
ID % inhibition at 10 µM 
VS12 60 79 43 <5 19 
VS18 80 <5 80 <5 80 
VS23 80 40 80 <5 70 
 
Compounds VS18 and VS23 had some effect on CYP1A2, CYP2C19 and CYP3A4. 
Compound VS12 inhibited CYP1A2 and CYP2C9.  
 
The intestinal permeability of compounds was evaluated in the human Caco-2 
model, in which the flux of the test compound from the apical (A) to the basolateral 
(B) side (together with B to A) is measured in order to predict the absorption from the 
lumen of the gut. 
 













VS12 39 35 0.9 
VS18 65 99 1.1 
VS23 94 109 0.8 
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Permeability of the three compounds was good. 
In the attempt to increase metabolic stability of the compounds the three hits were 
chemically modified in order to originate three different families of compounds and to 
be able to identify an optimized lead compound with improved ADME properties. The 
nature of the chemical modifications can not be revealed in this thesis due to 
intellectual property constraints. 
The newly synthesized compounds were retested through the screening platform in 
order to detect activity and toxicity profiles of the compounds.  
 
Table 7. Activity and toxicity profiles of newly synthesized compounds  
 
Compound 







VS12-A 0,04 0,3 0,08 (EST) 15 375 50 
187 
(EST) 
VS12-B 0,003(EST) 0,1 <0,08 7 2333 70 >87 
VS12-C <0,003 0,05 0,03 5 >1667 100 167 
VS12-D <0,003 0,08 0,09 (EST) 12 >4000 150 133 
VS12-E <0,003 0,4 0,04 10 >3333 25 250 
VS12-F 0,016 0,4 >0,08 15 938 38 <187 
VS18-A 0,03 0,4 0,05 15 500 38 300 
VS18-B 0,03 0,4 <0,08 20 (EST) 667 50 >250 
VS18-C 0,008 0,02 <0,08 5 625 250 >62 
VS18-D 0,01 0,03 <0,08 10 1000 333 >125 
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Compound 







VS18-E <0,003 <0,003 -  6 >2000 >2000 -  
VS18-F <0,08 <0,08  - 4 >50 >50  - 
VS18-G 0,008 0,05 <0,08 15 1875 300 >187 
VS18-H 0,06 (EST) 0,3  - 3 (EST) 50 10 -  
VS18-I 0,007 0,04  - 12 1714 300 -  
VS18-L 0,06 >0,4  - 12 200 <30 -  
VS18-M 0,1 >0,4  - 4 40 <10 -  
VS23-A 0,25 >0,4  - >20 >80 >50 -  
VS23-B 0,2 0,6  - 10 50 17 -  
VS23-C 0,08 0,4 -  >2 >25 >5  - 




Compounds were also tested for ADME properties determination and again the 
following parameters were examined: permeability in Caco-2 cells, metabolic stability 
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Table 8. ADME parameters of the newly synthesized compounds 
 





CYP450 % inhibition                           






(10-6cm/s) human rat 1A2 2C9 2C19 2D6 3A4 
VS12-A 49 22 183 <115,5 57 28 35 8 38 
VS12-B 46 27 <115,5 <115,5 66 26 28 5 32 
VS12-C 61 27 <115,5 <115,5 37 31 45 11 41 
VS12-D 60 29 <115,5 <115,5 21 17 19 4 30 
VS12-E 46 36 <115,5 <115,5 29 20 30 10 46 
VS12-F 46 26 <115,5 119 26 38 62 5 44 
VS18-A 55 23 411 <115,5 70 28 71 3 80 
VS18-B 72 17 501 <115,5 84 28 78 23 82 
VS18-C 51 15 625 <115,5 81 46 80 7 84 
VS18-D 53 9 744 216 93 48 90 45 87 
VS18-E 59 12 949 148 85 47 84 19 88 
VS18-F 48 19 268 897 78 59 88 21 88 
VS18-G 83 20 535 <115,5 75 21 90 0 82 
VS18-H 76 8 550 <115,5 50 23 52 9 55 
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CYP450 % inhibition                           






(10-6cm/s) human rat 1A2 2C9 2C19 2D6 3A4 
VS18-I 62 17,7 390,1 <115,5 83 44 74 9 82 
VS18-L 52,8 7,9 1168,8 561,2 85 31 88 24 79 
VS18-M 72,8 26 767,7 148,1 61 32 86 37 94 
VS23-A 50,9 16,5 356,4 <115,5 57 21 68 9 32 
VS23-B 34,7 9,8 477,4 <115,5 62 29 78 8 62 
VS23-C 35 13,8 417,6 <115,5 82 44 88 38 71 
VS23-D <0,4 0 -  -  50 15 74 8 22 
 
 
Compounds VS12-C, VS12-E and VS12-F showed promising ADME parameters 
(good permeability, metabolic stability and CYP450 inhibition profile) and were 
selected for a preliminary in vivo experiment in rodents aimed at determining the oral 
bioavailability of the compounds and selecting a clinical candidate compound to be 
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Table 9. Pharmacokinetic parameters after intravenous administration of the 
compounds 

























VS12-C 48 18 47 3231 917 42743 42907 
VS12-E 109 26 27 4109 908 73494 74468 
VS12-F 134 23 46 9139 1420 45740 46181 
 
Table 10. Pharmacokinetic parameters after oral administration (PO) of the 
compounds. 















VS12-C 63 30 1482 31 68 135368 136834 
VS12-E 42 30 2211 26 60 154169 154343 
VS12-F 36 30 1004 119 113 81328 82372 
 
 
Compound VS12-C resulted to be the compound with better bioavailability (FPO, the 
fraction of the administered compound that reaches systemic circulation) compared 
to the other ones.  This compound had also a promising activity/toxicity profile, as 
shown below.  
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Compound VS12-C had a good activity and toxicity profile with optimal therapeutic 
indexes. This compound was moved forward into preclinical development to further 
in vivo studies to determine tolerability and toxicokinetic profile. 
 
4.9. Preliminary toxicology study 
Aim of this study was to collect preliminary information on the toxic profile of 
compound VS12-C after single oral treatment at 500 mg/kg (formulated as a 
suspension) and after 5-day repeated treatment at 100 mg/kg (formulated as a 
solution) in the mouse. The mouse was chosen in order to use a small amount of 
compound in this preliminary test. Satellite groups were also treated in parallel in 
order to evaluate the plasma exposure after the administration of 500 mg/kg in 
suspension and prior and after the fifth day of treatment at 100 mg/kg. 
 
During the repeated 5-day treatment at 100 mg/kg/day no relevant clinical signs and 
no mortality were observed during the whole treatment. No statistically significant 
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After acute treatment at 500 mg/kg three animals were found dead 24 hrs after 
compound administration. Two animals were sacrificed in extremis 24 hrs after the 
compound administration because they were in pre-agonic status. The necroscopy 
performed on these animals indicated gastric problems with a moderated to severe 
presence of coagulated blood in stomachs. 
Plasma of the satellite groups were analysed to correlate the toxicological effects.   
No significant accumulation of the compound was found after administration of 100 
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Pharmacokinetic parameters are reported in Table 11.  
 
Table 11. Pharmacokinetic parameters of VS12-C after 5 days repeated treatment at 
100 mg/kg 
 
PO 100 mg/Kg Mean SD 
T1/2 (hr) 7.92 1.00 
Tmax (hrs) 1.67 2.02 
Cmax (μg/ml) 8.77 4.92 
Tlast (hrs) 48 - 
Clast_obs μg/ml 0.18 0.71 
AUC0-t (μg/ml*hr) 74.03 33.68 
















100mg/kg rip 5daysVS12-C 100 mg/kg 
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A large exposure variability was found within the subjects treated with the 
suspension at 500 mg/kg (Figure 11) and plasma levels showed an erratic exposure 
probably due to the precipitation and re-dissolution of the compound after oral 
gavage.  
 














Pharmacokinetic parameters are reported in Table 12.  
 
Table 12. Pharmacokinetic parameters for single treatment at 500 mg/kg  
PO 500 mg/Kg Mean SD 
T1/2 (hrs) 6.46 0.78 
Tmax (hrs) 7.20 9.44 
Cmax (μg/ml) 7.08 5.82 
Tlast (hrs) 40.8 17.2 
Clast_obs μg/ml 0.06 0.03 
AUC0-t (μg/ml*hrs) 74.03 33.68 



















VS12-C 500 mg/kg 
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As it can be observed from Figure 12 exposure at 500 mg/kg was comparable with 
that achieved at 100 mg/kg therefore the toxicological effects could not be attributed 
to a systemic exposure but probably to a local toxicity due to the precipitation of the 
compound in the stomach. Ratio between the AUC at 500 and 100 mg/kg  is only 
1.35 confirming a better exposure of the solution compared to the tested suspension.  
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4.10. Activity against other viruses 
CDK9 is involved in the life cycle of viruses other than HIV so it was decided to test 
the activity of a representative set of compounds against a panel of different viruses 
to explore potential activity of CDK9 inhibitors. 
 
Table 13. Activity of compounds against Herpes virus type 1 and 2 
  HSV-1 HSV-2 
Compound  EC50 µM CC50 SI50 EC50 µM CC50 SI50 
Acyclovir 2.9 >100 >35 3.9 >100 >26 
VS1 >100 >100 1.0 >100 >100 1.0 
VS2 >20 89.1 <4 >20 89.1 <4 
VS3 >20 89.4 <4 >20 89.4 <4 
VS4 >20 43.3 <2 >20 43.3 <2 
VS5 >20 78.2 <4 >20 78.2 <4 
VS6 >20 91.5 <5 >20 91.5 <5 
VS7 >20 72.9 <4 >20 72.9 <4 
VS8 >20 96.5 <5 >20 96.5 <5 
VS9 0.6 54.4 91.0 3.2 54.4 17.0 
VS10 >20 71.6 <4 >20 71.6 <4 
VS11 >20 87.3 <4 >20 87.3 <4 
VS12 >20 88.9 <4 >20 88.9 <4 
VS13 >100 >100 1.0 >100 >100 1.0 
VS14 >100 >100 1.0 >100 >100 1.0 
VS15 >4 19.8 <5 >4 19.8 <5 
VS16 >4 19.9 <5 >4 19.9 <5 
VS17 >20 59.2 <3 >20 59.2 <3 
VS18 >20 95.3 <5 >20 95.3 <5 
 
Compound VS9 resulted very active against both HSV-1 and HSV-2 with a selectivity 
index (SI50=CC50/EC50) of 91 and 17 for the two viruses, respectively. 
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Compounds were also tested against EBV, results are described in the following 
table. 
 
Table 14. Activity against Epstein-Barr Virus 
  EBV 
Compound EC50 µM CC50 SI50 
Acyclovir 17.4 >100 >6 
VS1 0.5 1.1 2.0 
VS2 <0.48 <0.48 1.0 
VS3 <0.48 <0.48 1.0 
VS4 >0.48 2.0 <4 
VS5 >2.40 2.6 <1 
VS6 <0.48 <0.48 1.0 
VS7 4.8 11.5 2.0 
VS8 1.2 8.1 8.0 
VS9 >0.48 1.0 <2 
VS10 0.7 2.0 3.0 
VS11 >2.40 9.2 <4 
VS12 7.7 11.0 1.0 
VS13 >12 26.0 <2 
VS14 >2.40 6.1 <3 
VS15 2.8 6.5 2.0 
VS16 <0.48 7.9 >16 
VS17 0.9 2.2 2.0 
VS18 >2.40 6.6 <3 
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Activity of CDK9 inhibitors against HPV was assayed, results are depicted in the 
following table. 
 
Table 15. Activity of CDK9 inhibitors against Human Papilloma Virus 
  HPV 
Compound EC50 µM EC90 CC50 SI50 SI90 
Cidofovir 148.0 >200 >200 >1 >1 
VS1 33.2 >100 >100 >3 1.0 
VS2 11.5 >100 >100 >9 1.0 
VS3 48.7 >10 85.8 2.0 <9 
VS4 1.7 20.0 >100 >60 >5 
VS5 26.7 54.8 >100 >4 >2 
VS6 9.7 14.0 >100 >10 >7 
VS7 >100 >100 >100 1.0 1.0 
VS8 1.8 41.7 >100 >54 >2 
VS9 9.4 28.9 35.9 4.0 1.0 
VS10 29.1 43.4 49.9 2.0 1.0 
VS11 0.5 90.8 >100 >185 >1 
VS12 39.0 90.2 >100 >3 >1 
VS13 16.7 55.4 >100 >6 >2 
VS14 28.6 48.1 >100 >4 >2 
VS15 >1 >1 8.3 <8 <8 
VS16 17.2 35.3 >100 >5 >3 
VS17 0.3 40.8 >100 >323 >3 
VS18 9.9 30.4 >100 >10 >3 
 
Compounds VS2, VS4, VS8, VS11, VS17 and VS18 were strongly active against 
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4.11. Activity against cancer cell lines 
The antiproliferative effect of selected CDK9 inhibitors was investigated in vitro in the 
following cancer cell lines: A2780 (Ovarian cancer), H1299 (Lung cancer), MNK45 
(Gastric cancer), HEC1A (Endometrial cancer) and Jurkat (T cell leukemia). 
Dose-response curves (mean of two experiments) of five selected compounds were 
obtained for each cancer cell line.  
 




























































Davide De Forni 
Antiviral-Hyperactivation limiting therapeutics for the treatment of viral diseases and cancer  

































































































Davide De Forni 
Antiviral-Hyperactivation limiting therapeutics for the treatment of viral diseases and cancer  
International PhD School in Biomolecular and Biotechnological Sciences - University of Sassari 
49 
A summary of the IC50 values obtained through the interpolation of the dose-
response curves of two different experiments is shown in the following table. 
 
Table 16. Summary of the IC50 values of the compounds analyzed in the five cancer 
cell lines 
 
Compound ID CDK9 IC50 nM 












Jurkat                     
(T Cell 
Leukemia) 
VS11 54 7.0555 27.175 8.461 43.15 5.161 
VS13 17 2.7965 5.683 7.9665 23.95 1.8 
VS20 26 0.46 17.1 8 52.1 0.255 
VS93 56 6.2 15.2 6.19 25.9 1.955 
VS136 46 7.8815 35.3 8.14 22.283 7.705 
 
 
The clinical candidate for the HIV/AIDS program VS12-C was also tested in lung 
cancer cell line (H1299) and proved to be active in inhibiting tumor cell line 
proliferation.  
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4.12. Activity in mouse xenograft model of lung cancer 
Compound VS12-C was tested in a lung cancer (H1299) mouse xenograft model. 
The experiment was performed in collaboration with Mario Negri Institute (Milan). 
Athymic female mice were injected with a cell suspension containing H1299 cells, 
when tumor load reached the proper size mice were randomized to receive vehicle 
(5% NMP, 85% PEG400, 10% water) or compound at 50 mg/kg/day by oral 
administration. Tumor size and mouse body weight were recorded three times a 
week from treatment start until the end of the study after 15 days of treatment. 
Treatment was well tolerated with apparent no signs of toxicity. 
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A growth inhibitory effect on the tumor mass was observable. 
After treatment cessation (Day 35 from tumor implant) the curve inclination in the 
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Immune system hyperactivation/hyperproliferation/inflammation occurs most rapidly 
and to the greatest extent in HIV/AIDS. Upon infection by HIV, it is actually the 
subsequent uncontrolled immune system hyperactivation that ultimately results in 
immune exhaustion, loss of CD4+ T helper cells, accelerated senescence (aging), 
cardiovascular and other organ diseases, and, consequently, the onset of AIDS. The 
chronic level of excessive inflammation seen in HIV is now recognized as a primary 
driver of a growing number of “non-AIDS defining events” that negatively affect both 
quality of life and life expectancy in HIV-infected individuals. These include 
cardiovascular diseases (including strokes and heart attacks), inflammatory and 
metabolic disorders, as well as liver, kidney and CNS disease, bone loss, and 
increased rates of cancer. Advances in HIV drug therapy today allow most patients 
to reduce the amount of virus in their bloodstreams to undetectable levels by use of 
antiretroviral treatment (ART) multi-drug cocktails. Despite the ability of such anti-
HIV cocktails to effectively reduce viremia, HIV patients still progress to AIDS and 
continue to suffer a reduced life expectancy due to a number of diseases resulting 
from uncontrolled immune system hyperactivation. The possibility of reducing both 
immune hyperactivation and viral load in HIV-infected subjects has been proven by 
the first AV-HALT drug, VS411 (originally developed by ViroStatics), an experimental 
combination of two registered drugs that has provided essential human Proof of 
Concept for this new class of drugs. Focus of the work was then to identify AV-HALT 
compounds combining antiviral and antiproliferative activity in a single molecule. 
These compounds possess a novel antiviral mechanism of action compared to 
traditional ARVs used in combination regimens currently on the market, i.e. targeting 
a human rather than a viral enzyme. Such compounds have been identified upon 
testing libraries of inhibitors of CDK9, which has been reported as essential for HIV-1 
replication and also involved in cell proliferation. CDK9 in complex with cyclin T1 is 
involved in viral genes transcription as it promotes processivity of RNAPII and is also 
involved in cell proliferation as its kinase activity is involved in promoting recovery 
from replication arrest in stress responses at the G2/M check point (Zhang 2013). 
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By testing toxicity, antiproliferative capacity and antiviral activity of compounds, a 
number of AV-HALT “drug hits” (compounds with the desired in vitro AV-HALT 
profile) having optimal therapeutic indexes have been identified. Such compounds, 
belonging to similar but distinct classes of molecules, share AV-HALT properties 
similar to the “proof-of-concept” reference standard VS411, making them suitable for 
drug development. 
A crucial part of the project was focused on the preclinical development of the 
compounds. Different ADME parameters have been evaluated to select not only 
compounds that are active in vitro but also compounds that are suitable for drug 
development. In particular, the following sets of data were pursued:  
a) Investigation of the potential of AV-HALT compounds to inhibit human CYP450 
activity in vitro, evaluating the CYP450 interaction of such compounds with the five 
most important isoforms enzyme;  
b) Investigation of AV-HALT compound clearance with liver microsomes, evaluating 
the metabolic stability of such compounds in rat and human liver microsomes in 
order to estimate stability to phase I oxidative metabolism;  
c) Caco-2 permeability assessment to investigate possible efflux phenomena;  
d) Solubility studies.  
 
The first hit compounds had some drawbacks, mainly dealing with the low metabolic 
stability. This means that the drug candidates may have the potential to form 
undesired, potentially toxic, or pharmacologically inactive/active metabolites. The 
issue has been addressed and solved by inserting some chemical modifications 
(substituents) in order to improve metabolic stability of the compounds.  
 
We also learnt that solubility is an important issue for this class of CDK9 inhibitors. It 
is generally desirable for a drug molecule to have some level of water solubility. 
These compounds showed very poor solubility in acqueous ambient (about 1 µM in 
phosphate buffer pH 7.4). Low solubility can translate into poor and varying 
bioavailability, can slow down the overall development process, can lead to 
increased development costs and to the development of a suboptimal drug for the 
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patient. Poor water solubility can be addressed with a good formulation work. In fact 
we are already developing a new formulation to improve solubility and increase drug 
exposure in vivo. An excellent enabling formulation strategy is the nanosizing (e.g., 
wet bead milling) technology. Drug nanocrystal technology has emerged in the last 
15-20 years mainly due to the benefits that can be gained by formulating poorly 
soluble drugs. This approach generally produces dispersions of drug nanocrystals in 
a liquid medium (typically water), which are called “nanosuspensions”. 
Nanosuspensions consist essentially of pure drug nanoparticles (100–1000 nm) and 
a minimum amount of surface active agents and polymers required for stabilization. 
This technology can significantly enhance the effective surface area of the drug, thus 
resulting in increased exposure. 
 
Through the in vitro screening platform and several rounds of ADME parameters 
characterization we were able to improve the activity and druggability characteristics 
of the molecules. We have now identified a lead second generation AV-HALT with 
optimal activity and toxicity profile in vitro, with promising ADME properties and good 
oral bioavailability. Further studies are underway to complete VS12-C preclinical 
development and better elucidate the mechanism of action. 
 
CDK9 as a cellular factor is involved in life cycle of many other pathogens. There 
was a good rationale to test activity of CDK9 inhibitors against other viruses such as 
HSV-1/2, EBV and HPV. Several compounds have been identified that strongly 
inhibited replication of these viruses with a good therapeutic window. It will be 
important to explore the molecular mechanisms responsible for the activity. 
 
Deregulation of cyclin-dependent kinases has been associated with many cancer 
types and has evoked an interest in chemical inhibitors with possible therapeutic 
benefit. Recently work highlighted CDK9 as a critical target responsible for the 
activity of several drugs currently under clinical development.  We tested our library 
of CDK9 inhibitors and found several compounds active in vitro against several 
cancer cell lines.  In particular compound VS12-C proved to possess good 
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